Clinical Trial: A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06909214) titled 'A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)' on March 27.

Brief Summary: The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: New Onset Generalized Myasthenia Gravis (gMG)

Intervention: BIOLOGI...